The Latest Cardiac and Vascular News
NEW YORK–(BUSINESS WIRE)–ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio agreement with Johnson & Johnson to support the adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers (ASC) across the United States. The agreement encompasses an integrated portfolio of three-dimensional mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies. The co
Irvine, CA – July 8, 2026 – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF), an integrated catheter ablation solution that enables electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF) energy through […]
IRVINE, Calif.–(BUSINESS WIRE)–Johnson & Johnson advances cardiac ablation technology in Europe with availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform.
SANTA CLARA, Calif.–(BUSINESS WIRE)–Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
NEW BRUNSWICK, N.J. – April 24, 2026 – Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Atraverse Medical, Inc., a privately-held medical device company pioneering next-generation left-heart access and radiofrequency (RF) technology. Achieving safe and precise access to the left atrium remains one of the most critical steps […]
– TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. – Approval builds on a trusted solution in neurovascular embolization for over 25 years. IRVINE,…
